Protective, Tumor-selective Dual Pathway Activation of 5-Fluoro-2 ′-deoxycytidine Provided by Tetrahydrouridine in Mice Bearing Mammary Adenocarcinoma-755 David A. Boothman, Thomas V. Briggle and Sheldon Greer Cancer Res 1987;47:2344-2353. Published online May 1, 1987.
Updated Version
Citing Articles
E-mail alerts Reprints and Subscriptions Permissions
Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/47/9/2344
This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/47/9/2344#related-urls
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
[email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at
[email protected].
Downloaded from cancerres.aacrjournals.org on July 10, 2011 Copyright © 1987 American Association for Cancer Research
[CANCER RESEARCH 47, 2344-2353, May 1, 1987]
Protective, Tumor-selective Dual Pathway Activation of 5-Fluoro-2'-deoxycytidine Provided by Tetrahydrouridine in Mice Bearing Mammary Adenocarcinoma-7551 David A. Boot liman,2 Thomas V. Briggle, and Sheldon Greer3 Departments of Microbiology and Immunology [D. A. B., S. G.J, Oncology and Biochemistry [S. GJ, and Biochemistry, Epidemiology, and Public Health [T. V. BJ, School of Medicine, University of Miami, Miami, Florida 33101
optimal drug doses against solid and ascitic ADC-755 and against Lewis lung carcinoma in its solid form (Cancer Res., 44: 2551-2560,1984).
ABSTRACT Treatment of C57BL x DBA/2 F, (hereafter called BD2F,) mice bearing ascitic mammary adenocarcinoma-755 (AIM'-755) with |'H|-5fluoro-2'-deoxycytidine (|3H]FdCyd) plus tetrahydrouridine (H
